文献速递皮肤肿瘤毛发、甲与色素性疾病

肺癌抗PD-1/PD-L1治疗期间毛发复色

Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
PubMed 文献 · JAMA Dermatol · 2017-01-01

该病例系列描述14例非小细胞肺癌患者在接受抗PD-1或抗PD-L1治疗期间出现毛发复色,表现为弥漫性毛发变黑或白发间黑斑。13例患者对治疗有良好临床反应(至少疾病稳定),提示毛发复色可能是治疗反应的标志。

要点

  • 抗PD-1/PD-L1治疗肺癌期间可观察到毛发复色。
  • 毛发复色表现为弥漫性变黑或白发间黑斑。
  • 毛发复色可能与良好的治疗反应相关。

核心结论

  • 首次报告14例肺癌患者抗PD-1/PD-L1治疗期间出现毛发复色,可能是良好反应标志。

主要发现

  • 14例患者(13男1女,平均年龄64.9岁)接受抗PD-1或抗PD-L1治疗非小细胞肺癌,随访中出现毛发复色。
  • 13例表现为弥漫性毛发变黑,1例为白发间黑斑。
  • 13例对治疗有良好临床反应(至少疾病稳定),仅1例因疾病危及生命的进展在4周期后停药。

临床怎么用

  • 接受抗PD-1/PD-L1治疗的肺癌患者出现毛发复色时,可考虑作为治疗反应的潜在标志。

局限性

  • 病例系列样本量小,为描述性观察,未设对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: New targeted therapies for cancer have been released in recent years, opening new horizons in the treatment of patients with cancer. However, their related adverse events (AE) are not fully characterized. Hair repigmentation (HR) is a nondescribed effect secondary to anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1 ) therapy for treatment of lung cancer (LC), in opposition to the vitiligo reactions that develop during melanoma treatment. OBJECTIVE: To describe a new adverse event occurring during anti-PD-1/anti-PD-L1 therapy for LC. DESIGN, SETTING, AND PARTICIPANTS: A case series from a descriptive observation of 14 patients with HR after anti-PD-1/anti-PD-L1 treatment, recruited between September and December, 2016, who were followed up to detect whether they developed cutaneous AE at the time HR was detected. The patients had all been treated in the dermatology department at Hospital Universitari Germans Trias i Pujol, Badalona, Spain. MAIN OUTCOMES AND MEASURES: Clinical observation of HR during anti-PD-1/anti-PD-L1 therapy for LC, proved by comparing old pictures provided by the patients and recent pictures taken during the follow-up. RESULTS: Fourteen patients (13 men and 1 woman; mean age, 64.9 years) receiving anti-PD-1 or anti-PD-L1 therapy for non-small-cell lung cancer (NSCLC) presented hair repigmentation during follow-up. This hair repigmentation consisted in a diffuse darkening of the hair in 13 of 14 patients, or in black patches between white hairs in 1. Thirteen of 14 patients presented a good clinical response to the treatment, with at least stable disease, and only 1 had to stop the therapy after only 4 cycles of treatment owing to a life-threatening progression of the disease. CONCLUSIONS AND RELEVANCE: We present to our knowledge the first report of hair repigmentation owing to anti-PD-1/anti-PD-L1 therapy for lung cancer in a series of 14 patients. Hair repigmentation may be a good response marker in patients receiving anti-PD1/anti-PD-L1 therapy for LC.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Rivera N, Boada A, Bielsa MI, et al. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. JAMA Dermatol. 2017. PMID: 28700789. doi:10.1001/jamadermatol.2017.2106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。